{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:03:30Z","timestamp":1763726610732,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T00:00:00Z","timestamp":1341273600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>To describe the institutional experience of plerixafor plus filgrastim as the initial peripheral blood stem cell (<jats:styled-content style=\"fixed-case\">PBSC<\/jats:styled-content>) mobilization (first\u2010line strategy) and as rescue therapy after failure with filgrastim plus cyclophosphamide (second\u2010line strategy).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective medical record review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Academic medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Thirty\u2010three patients (median age 62\u00a0yrs) who received plerixafor between <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 2008 and <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ecember 2009.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>We collected data on total <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cell yield and number of apheresis sessions in both first\u2010line and second\u2010line plerixafor recipients. Mobilization with plerixafor plus filgrastim resulted in a median yield of 8.95\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup> and 2.45\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup> <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup>\u00a0cells\/kg in patients with multiple myeloma or non\u2010Hodgkin's lymphoma, respectively. As rescue mobilization, plerixafor plus filgrastim successfully mobilized <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells in 16 (84%) of 19 patients. When comparing first\u2010line plerixafor plus filgrastim therapy with second\u2010line therapy, we found an increase in <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> yield and 1 less apheresis day in patients with <jats:styled-content style=\"fixed-case\">multiple myeloma<\/jats:styled-content>, but no difference in patients with <jats:styled-content style=\"fixed-case\">non\u2010Hodgkin's lymphoma<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A regimen of plerixafor plus filgrastim successfully mobilized <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells in a median of 1 apheresis day for patients with <jats:styled-content style=\"fixed-case\">multiple myeloma<\/jats:styled-content> and 2 apheresis days for patients with <jats:styled-content style=\"fixed-case\">non\u2010Hodgkin's lymphoma<\/jats:styled-content>, including patients who failed initial filgrastim plus cyclophosphamide mobilization. Plerixafor plus filgrastim could be a viable first\u2010line option in patients with <jats:styled-content style=\"fixed-case\">multiple myeloma<\/jats:styled-content>, as it improved <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cell yield and decreased number of apheresis days compared with second\u2010line plerixafor plus filgrastim therapy, whereas it was comparable to second\u2010line therapy in patients with non\u2010Hodgkin's lymphoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/j.1875-9114.2012.01096.x","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T03:55:01Z","timestamp":1346817301000},"page":"596-603","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Plerixafor as First\u2010 and Second\u2010Line Strategies for Autologous Stem Cell Mobilization in Patients with Non\u2010<scp>H<\/scp>odgkin's Lymphoma or Multiple Myeloma"],"prefix":"10.1002","volume":"32","author":[{"given":"Kevin W.","family":"Lor","sequence":"first","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter J.","family":"Helmons","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Belew","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation Department of Medicine University of California San Diego Medical Center San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation Department of Medicine University of California San Diego Medical Center San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G\u2010CSF versus placebo and G\u2010CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"23","author":"DiPersio JF","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.409"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01440.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2059"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10245332.1999.11746443","article-title":"Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r\u2010metHuG\u2010CSF): The CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high\u2010dose chemotherapy","volume":"3","author":"Sola C","year":"1999","journal-title":"Hematology"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.93"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703575"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","article-title":"Factors that influence collection and engraftment of autologous peripheral\u2010blood stem cells","volume":"10","author":"Bensinger W","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood.V86.10.3970.bloodjournal86103970","article-title":"Autologous progenitor cell transplantation: prior exposure to stem cell\u2010toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts","volume":"10","author":"Dreger P","year":"1995","journal-title":"Blood"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701671"},{"key":"e_1_2_7_13_1","unstructured":"Cyclophosphamide package insert. Available fromhttp:\/\/patient.cancerconsultants.com\/druginserts\/Cyclophosphamide.pdf. Accessed on April 1 2011."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2003.n.002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.2012.01096.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.2012.01096.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:42:57Z","timestamp":1761046977000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.2012.01096.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1002\/j.1875-9114.2012.01096.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.2012.01096.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2012-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}